360
Participants
Start Date
June 19, 2023
Primary Completion Date
June 30, 2027
Study Completion Date
December 31, 2028
Anlotinib Hydrochloride Capsule
Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor that inhibits both tumor angiogenesis and tumor cell proliferation simultaneously.
RECRUITING
Beijing Tongren Hospital Affiliated to Capital Medical University, Beijing
RECRUITING
Liaoning Cancer Hospital and Institute, Shenyang
RECRUITING
Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University, Nanjing
RECRUITING
Jiangsu North People's Hospital, Yangzhou
NOT_YET_RECRUITING
Anhui Provincial Cancer Hospital, Hefei
RECRUITING
Tianjin People's Hospital, Tianjin
RECRUITING
Tianjin Cancer Hospital, Tianjin
RECRUITING
Zhejiang Provincial People's Hospital, Hangzhou
NOT_YET_RECRUITING
Hunan Cancer Hospital, Changsha
RECRUITING
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan
RECRUITING
Hubei Cancer Hospital, Wuhan
RECRUITING
Henan Cancer Hospital, Zhengzhou
RECRUITING
The First Affiliated Hospital of Zhengzhou University, Zhengzhou
NOT_YET_RECRUITING
Guangxi Zhuang Autonomous Region Cancer Hospital (Affiliated Cancer Hospital of Guangxi Medical University), Nanning
RECRUITING
The First Affiliated Hospital of Kunming Medical University, Kunming
RECRUITING
The First Affiliated Hospital of Xi'an Jiaotong University, Xi’an
NOT_YET_RECRUITING
Shanxi Provincial Tumor Hospital, Xi’an
RECRUITING
Gansu Cancer Hospital, Lanzhou
RECRUITING
The First Affiliated Hospital of Hebei North University, Shijiazhuang
Lead Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
INDUSTRY